Renuka Ramanathan1, Jaehyung Park1, Sean M Hughes2, William R Lykins1, Hunter R Bennett1, Florian Hladik2,3,4, Kim A Woodrow1. 1. Department of Bioengineering, University of Washington, Seattle, WA, USA. 2. Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA. 3. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 4. Department of Medicine, University of Washington, Seattle, WA, USA.
Abstract
PROBLEM: The capacity of antigen-carrying vaccine nanoparticles (NPs) administered vaginally to stimulate local immune responses may be limited by the relatively low numbers of antigen-presenting cells (APCs) in the genital mucosa. Because inflammation is associated with increased susceptibility to sexually transmitted infections, we sought to increase APC numbers without causing inflammation. METHOD OF STUDY: In this study, we evaluated intravaginal delivery of chemokines, growth factors, or synthetic adjuvants to expand APCs in reproductive tissues. RESULTS: We found that granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulated expansion of CD11b+ dendritic cells (DCs) within 24 hr of intravaginal administration, with no effect on Langerhans cells or macrophages. Expansion of the CD11b+ DC population was not associated with increased inflammatory cytokine production, and these cells retained phagocytic function. CONCLUSION: Our data suggest that non-inflammatory expansion of mucosal APCs by intravaginal GM-CSF could be used as an adjuvanting strategy to potentiate the genital immune response to nanoparticulate mucosal vaccines.
PROBLEM: The capacity of antigen-carrying vaccine nanoparticles (NPs) administered vaginally to stimulate local immune responses may be limited by the relatively low numbers of antigen-presenting cells (APCs) in the genital mucosa. Because inflammation is associated with increased susceptibility to sexually transmitted infections, we sought to increase APC numbers without causing inflammation. METHOD OF STUDY: In this study, we evaluated intravaginal delivery of chemokines, growth factors, or synthetic adjuvants to expand APCs in reproductive tissues. RESULTS: We found that granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulated expansion of CD11b+ dendritic cells (DCs) within 24 hr of intravaginal administration, with no effect on Langerhans cells or macrophages. Expansion of the CD11b+ DC population was not associated with increased inflammatory cytokine production, and these cells retained phagocytic function. CONCLUSION: Our data suggest that non-inflammatory expansion of mucosal APCs by intravaginal GM-CSF could be used as an adjuvanting strategy to potentiate the genital immune response to nanoparticulate mucosal vaccines.
Authors: Marie Le Borgne; Nathalie Etchart; Anne Goubier; Sergio A Lira; Jean Claude Sirard; Nico van Rooijen; Christophe Caux; Smina Aït-Yahia; Alain Vicari; Dominique Kaiserlian; Bertrand Dubois Journal: Immunity Date: 2006-02 Impact factor: 31.745
Authors: S Vadhan-Raj; H E Broxmeyer; W N Hittelman; N E Papadopoulos; S P Chawla; C Fenoglio; S Cooper; E S Buescher; R W Frenck; A Holian Journal: J Clin Oncol Date: 1992-08 Impact factor: 44.544
Authors: Daniel Prantner; Toni Darville; James D Sikes; Charles W Andrews; Helmut Brade; Roger G Rank; Uma M Nagarajan Journal: Infect Immun Date: 2009-10-05 Impact factor: 3.441
Authors: Sachin M Apte; Saroj Vadhan-Raj; Lorenzo Cohen; Roland L Bassett; Ilyssa O Gordon; Charles F Levenback; Pedro T Ramirez; Stacie T Gallardo; Rebecca S Patenia; Michael E Garcia; Revathy B Iyer; Ralph S Freedman Journal: J Transl Med Date: 2006-04-07 Impact factor: 5.531
Authors: Byron Ballou; Susan K Andreko; Elvira Osuna-Highley; Michael McRaven; Tina Catalone; Marcel P Bruchez; Thomas J Hope; Mohamed E Labib Journal: PLoS One Date: 2012-12-21 Impact factor: 3.240